Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

not met at the highest dose evaluated as monotherapy (1000 mg). - No evidence of altered cardiac activity was observed. - Majority of adverse events were mild and mainly occurred during the loading doses. Adverse events consisted of chills, itching and fatigue in over a third of patients. - There was a trend for increasing incidence of some mild adverse events with escalating OGX-427 doses. For example, 33% of patients at the 200-mg dose compared to 67% of patients at the 1000-mg dose had mild adverse events during the loading doses. - The half-life of OGX-427 in the blood remained constant, although there appeared to be an increase in maximum blood levels and a corresponding decease in blood clearance of OGX-427 as doses were escalated.

The combination of 800 mg OGX-427 with docetaxel was also well tolerated and escalation to 1000 mg OGX-427 with docetaxel will be evaluated next.

Circulating Tumor Cell and Tumor Marker Results

Circulating tumor cells (CTCs), an emerging metric to assess treatment effect, was evaluated at baseline before treatment and during treatment. Both total and Hsp27-positive CTCs were evaluated. Declines of 50% or greater in both total and Hsp27-positive CTCs were observed in over half of the patients in each cohort and in each cancer category. Declines in Hsp27 CTCs to 5 or less cells occurred in 27% of patients who had greater than 5 CTCs at baseline.

Reduction in tumor markers defined as declines of PSA levels in prostate cancer or CA-125 levels in ovarian cancer were also observed. A reduction in PSA level was observed in 7 of 20 patients (35%) with prostate cancer and a reduction in CA-125 levels was observed in 3 of 5 patients (60%) with ovarian cancer.

"CTCs are emerging as an exciting surrogate of anti-cancer activity. The frequent decreases in total
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 Reports from ... United States suffer from one or more chronic health ... cancer. Medication can address some of these diseases, but ... that many sufferers face. While implanted nerve stimulation devices ... the whole nerve, which can induce side effects. ...
(Date:12/19/2014)... 2014  Decision Resources Group finds that the ... grow moderately through 2023 as the aging population, increasing ... dental biomaterials all spur procedure volumes. Growth will be ... China and India , ... reach for a larger proportion of the population. ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Based ... the overall surgical imaging market is dominated by ... the surgical imaging market. These players include GE ... Ziehm Imaging (Germany). , Full Report Copy ... of GE Healthcare can be attributed to its ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 This ... Global Quartz Tubing industry. For an overview analysis, ... classification, application, industry chain structure, industry overview, policy ... quartz tubing industry has witnessed rapid development ... number of acquisitions. This report mentions quartz tubing ...
Breaking Biology Technology:Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 42020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2
... to a multiplex near you, but movies showing the ... have blockbuster potential. A team of scientists with the ... of California (UC) Berkeley has developed a technique for ... that chemical reactions in the liquids can be imaged ...
... development of new applications based on nanoimprinting techniques (NIL) is ... challenges to be overcome in order to reach the market? ... its uptake from the industry? What are the tools needed ... exactly with this topic, i.e. Nanopatterning, Production and Applications based ...
... 20, 2012     On May 21-23, 2012, ... created to support, mentor, and develop minority-, woman-, ... host its fifth annual networking conference and EXPO ... health advocate, will address the conference held at ...
Cached Biology Technology:First atomic-scale real-time movies of platinum nanocrystal growth in liquids 2First atomic-scale real-time movies of platinum nanocrystal growth in liquids 3First atomic-scale real-time movies of platinum nanocrystal growth in liquids 4First atomic-scale real-time movies of platinum nanocrystal growth in liquids 5Low-cost optical components through nanoimprinting lithography 2Low-cost optical components through nanoimprinting lithography 3Music Legend And Health Advocate Bret Michaels To Address Diversity Alliance For Science 2012 National Conference And EXPO 2Music Legend And Health Advocate Bret Michaels To Address Diversity Alliance For Science 2012 National Conference And EXPO 3
(Date:12/17/2014)... 2014  HITLAB SM announced today its ... to confirm its adherence to current U.S. Food ... HITLAB to conduct regulated smart device and smart ... patient safety and research quality. "HITLAB ... and delivery with innovative technology," said Laura ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... magazine, has won the 2009 Media Award of the American ... outstanding reporting on biological research in either print or broadcast ... 5 of a 6-part series in the magazine on scientists, ... sexual development. This segment of the series appeared in the ...
... glial (supporting) cells of the brain. Gliomas are often ... infiltrate normal brain tissue and, in addition, individual tumor ... is almost impossible to remove the tumor tissue completely ... the tumor would substantially improve the prognosis of patients. ...
... novel technique for carrying out gene-expression profiling is ... current, widely used methodology, reports Genetic Engineering ... scientists believe that digital gene-expression profiling, a fully ... microarrays in this application area, according to the ...
Cached Biology News:2009 AIBS Media Award 22009 AIBS Media Award 3Fluorescent cancer cells to guide brain surgeons 2
... Product Rabbit polyclonal to JNK1 ... peptide mapping to an internal domain containing phosphorylated ... Human, Mouse and Rat. Not yet tested in ... consist of several subgroups, including the ERK, JNK, ...
... potent Rnase free Ribonuclease Inhibitor ... broad range of temperatures and ... not inhibit SP6, T7, or ... M-MLV reverse transcriptase or Taq ...
Dako Target Retrieval Solution, Citrate pH 6 (x 10) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
... All the functionality of the micro1401 but ... and more available channels of waveform input ... option for programmable front-end gain. Can be ... waveform inputs and from 4 to 8 ...
Biology Products: